The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Focal adhesion kinase (FAK) inhibitors VS-6063 and VS-4718 target cancer stem cells.
Qunli Xu
Employment or Leadership Position - Verastem
Stock Ownership - Verastem
Vihren N Kolev
Employment or Leadership Position - Verastem
Stock Ownership - Verastem
Quentin G Wright
Employment or Leadership Position - Verastem
Stock Ownership - Verastem
Irina M Shapiro
Employment or Leadership Position - Verastem
Stock Ownership - Verastem
Christian M. Vidal
Employment or Leadership Position - Verastem
Stock Ownership - Verastem
Mahesh Padval
Employment or Leadership Position - Verastem
Stock Ownership - Verastem
Mitchell Keegan
Employment or Leadership Position - Verastem
Stock Ownership - Verastem
Daniel Paterson
Employment or Leadership Position - Verastem
Stock Ownership - Verastem
Joanna Horobin
Employment or Leadership Position - Verastem
Stock Ownership - Verastem
Jonathan A Pachter
Employment or Leadership Position - Verastem
Stock Ownership - Verastem